Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monsanto grants access to transformation method

Academic institutions and other not-for-profit organisations will be given a royalty-free research licence to a newly issued US patent awarded to Monsanto this month. The patent (US 8,273,954) covers an Agrobacterium tumefaciens-mediated transformation method for dicotyledonous plants. It was first filed in 1983. Royalty-free access to “one of the leading agricultural biotechnologies” will further the enablement and development of key agriculture solutions for farmers and consumers alike, says Robb Fraley, chief technology officer for Monsanto and a co-inventor named in the patent. Interested parties can access a downloadable request form for the research licence on Monsanto's website at www.monsanto.com. Monsanto's A tumefaciens transformation technology has been previously licensed to other major technology developers for commercial purposes. Commercial licences will continue to be available.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG012353

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel